Amgen Inc. $AMGN Stock Position Raised by Sigma Planning Corp

Sigma Planning Corp increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 34.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,816 shares of the medical research company’s stock after purchasing an additional 4,797 shares during the quarter. Sigma Planning Corp’s holdings in Amgen were worth $7,930,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Wellington Altus USA Inc. increased its stake in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares during the period. Nvwm LLC raised its position in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after buying an additional 66 shares during the last quarter. PFS Partners LLC raised its position in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after buying an additional 42 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Amgen in the 2nd quarter worth $36,000. Finally, Steph & Co. acquired a new stake in shares of Amgen in the 3rd quarter worth $42,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last quarter. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $439.26 on Monday. The business’s fifty day moving average price is $417.70 and its 200 day moving average price is $378.08. The firm has a market capitalization of $237.48 billion, a PE ratio of 27.30, a P/E/G ratio of 3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $450.98.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the company earned $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Truist Financial increased their price target on shares of Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a report on Wednesday, October 7th. TD Cowen increased their price target on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Oppenheimer restated an “outperform” rating on shares of Amgen in a research report on Friday. Finally, Sanford C. Bernstein lifted their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $389.71.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.